It exhibited outstanding anti-tumor activity in FGF19-expressing HCC cell lines with FGF19 amplification and intact FGFR4, as well as xenograft models with an intact FGFR4/KLB signaling pathway (Table 1) [175]. This evidence concerns the gene FGF19 and hepatocellular carcinoma.